Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0040-1706021
A Green, Scalable, and Catalyst-Free One-Minute Synthesis of Quinoxalines
Abstract
A highly efficient and catalyst-free protocol is reported for the synthesis of quinoxalines via the classical cyclocondensation reaction between aryldiamines and dicarbonyl compounds. Remarkably simple and green reaction conditions employing methanol as solvent afforded medium to excellent yield of quinoxalines after only one-minute reaction time at ambient temperature. The conditions allow at least 10 gram scale synthesis of quinoxalines and should be a preferred starting point for optimization and method of choice for applications in the synthetic community.
#
Quinoxaline is one of the truly important nitrogen-containing heterocycles and versatile building blocks for the synthesis of natural products, pharmaceutical agents,[1] and other biologically active compounds.[2] The scaffold is linked with a number of pharmacological activities such as anticancer-,[3] antifungal-,[4] antiviral-,[5] antimalarial-,[6] antibacterial-,[7] and immunosuppressive/antineoplastic activities[8] (Figure [1]). Moreover, the quinoxaline scaffold is also employed in a range of applications as dyes,[9] organic semiconductors,[10] anion receptors,[11] dehydroannulenes,[12] cavitands,[13] electroluminescent materials,[14] and DNA-cleaving agents.[15] Quinoxalines are central components of several important antibiotics such as echinomycin, levomycin, and actinoleutin.[16]
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202101/thumbnails/i_d0041_f1_10-1055_s-0040-1706021.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
The range of applications of quinoxalines has triggered the development of numerous synthetic methods for their synthesis.[17] The direct condensation between 1,2-aryldiamines and 1,2-dicarbonyl compounds has been known since the late 1800s and is, arguably, one of the most widely known reactions in organic chemistry.[17c] [d] A simple Scifinder search on the archetypical reaction between phenylenediamine and glyoxal reveals an astounding 48121 hits, truly underlining the power and widespread knowledge of this classical transformation. Some of the contemporary approaches towards quinoxalines also include the classical cyclocondensation and can be summarized as follows (Scheme [1]): (a) the condensation reaction between diamines and dicarbonyl compounds under reflux in ethanol or acetonitrile with catalyst or acid present,[18] (b) reaction between vicinal diols and diamines in the presence of variety of metal catalysts and strong bases,[19] (c) reaction with α-hydroxy ketones using MnO2 and CuCl2 as catalysts,[20] and (d) the condensation of diamines with α-halo ketones – used for the synthesis of quinoxalines in the presence of TMSCl and HClO4–SiO2 as heterogeneous catalysts at elevated temperatures.[21]
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202101/thumbnails/i_d0041_s1_10-1055_s-0040-1706021.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
There are several improvements in synthetic procedures reported using microwave irradiation,[22] solid-phase synthesis,[23] ultrasound,[24] as well as solvent-free[25] and room-temperature conditions.[25] Numerous catalyst systems have been reported for the synthesis of quinoxalines, including iodine,[26] acetic acid,[27] zeolites,[28] Ni nanoparticles,[29] ionic liquids,[30] NH4Cl,[31] Al2O3,[32] MnO2,[33] POCl3,[34] Pd(OAc)2,[35] cerium ammonium nitrate,[36] gallium triflate,[37] CuSO4·5H2O,[38] and sulfamic acid/methanol.[39] In general, the reported methods often require elevated temperatures, strong acid catalyst, stoichiometric oxidant, expensive metal catalysts, or relatively long reaction times to facilitate the reaction with reasonable synthetic efficiency. Moreover, many of these methods typically display low-atom economy and yield undesirable byproducts. Thus, the development of highly efficient, simple, and environmentally benign reaction conditions is an important goal. In this regard, it can be noted that roughly half of the Scifinder hits on the reaction between phenylenediamine and glyoxal were classified as uncatalyzed, i.e., occurred with only heating and/or prolonged reaction times. In this myriad of reported conditions, it is difficult to navigate when considering the synthesis of a specific quinoxaline. In this paper, we intend to convey with clarity where to start.
It is often difficult to find a rationale for the use of all the different catalysts and additives that have been reported. However, it is well known that the condensation reaction can be catalyzed by Lewis or Brønsted acids.[18] [19] Moreover, the shear diversity and quantity of reaction conditions reported suggest that the condensation is very robust and tolerant. With this perspective, we have aimed to overcome typical limitations and to identify the most practical and simple reaction conditions for this classical transformation from which any optimization work should start. Herein, we demonstrate a very simple, high-yielding/highly atom-economic protocol for the synthesis of quinoxalines using diamines and dicarbonyl compounds in methanol as solvent at room temperature with only one-minute reaction time. To our surprise, previous accounts have not described the broad use and scope of the very simplest conditions for the synthesis of quinoxalines.
We have recently published a rapid method for the synthesis of benzimidazoles[40] using only methanol as solvent at room temperature with one-minute reaction time. The unprecedented simplicity and efficiency of this system became the impetus for our current study, in which we investigate the synthesis of quinoxalines via 1,2-dicarbonyl compounds under similar experimental conditions. By mixing the reagents in 5 mL/mmol methanol at room temperature for one minute in a vessel open to air, the reaction between phenylenediamine 1a and glyoxal 2a gave impressive 99% GC conversion and 93% isolated yield of quinoxaline 3a (Table [1]).[41] The same reaction in ethanol also gave quantitative GC conversion, but somewhat less 85% isolated yield of 3a. A survey of other solvents revealed that a broad spectrum of reaction media can be employed, and 99% GC conversions were observed in acetonitrile, DMF, THF, ethyl acetate, and chloroform. There seems to be a consistent relation between the GC conversions and isolated yields.
a Reaction procedure: to a stirred solution of diamine 1 (100 mg, 0.925 mmol) in a specified solvent (5 mL), glyoxal 2 (40%, 0.11 mL, 0.925 mmol) was added and stirred for 1 min at ambient temperature.
b GC conversion of starting material.
c Isolated yield.
d 1, 10 mL mmol–1 of solvent.
Only acetone and water gave lowered conversions in this assay (77% and 60%, respectively) which appeared to be due to solubility problems in these solvents. The reaction is relatively insensitive to the concentration, as a control experiment with doubled amount of methanol (10 mL mmol–1) afforded the same full conversion and an only slightly diminished isolated yield of 88% after one-minute reaction time. Thus, the amount of solvent employed can probably be minimized but 5 mL mmol–1 was kept as standard for practical reasons. Based on this survey, the further studies were conducted in methanol although it should be noted that a range of solvents are viable.
We next studied various systems with different substituents on the diamine and the dicarbonyl components in order to ascertain the generality of the simple reaction conditions (Scheme [2]). Adding methyl groups, using either butane-2,3-dione or 4,5-dimethylphenylenediamine or both as the electrophile, did not significantly alter the outcome of the corresponding condensation products 3a–d which were formed in excellent 93–96% yields. Introducing halogens on the diamine, such as 3k,l led to diminished but still good yields (62–66%). The 7-bromo-5-chloro-disubstituted product 3e was also formed in similar yield (65%), whereas 6,7-dichloroquinoxaline (3g) was formed in 40% yield. Further tests with butane-2,3-dione and the dihalogenated diamines also displayed diminished yields in this series (29–55% yields). Compound 3f was formed in the lowest yield (29%) and even increasing the reaction time up to 30 minutes did not alter this outcome. The main problem appears to be that conversion of the starting material stops or becomes very slow (from GC analyses). The case of 3g was studied further to find a solution for improving the yields observed in the dihalogenated systems. Upon heating the reaction mixture in a microwave at 100 °C for 5 minutes, full conversion was observed, and 91% yield of 3g was isolated. Thus, heating is one effective solution, however, we were invested in finding as simple conditions as possible for rapid conversion into product. Conducting the reaction in acetic acid as solvent also gave full conversion of the starting material and 85% yield of 3g was isolated after one-minute reaction. This also suggests, not surprisingly, that the yield can be enhanced by acid catalysis, which was confirmed by an experiment in methanol adding 10 mol% of acetic acid, which also gave full conversion and comparable 82% isolated yield of 3g. The formation of product 3f was vastly improved to 98% yield upon microwave irradiation at 100 °C for 10 minutes. There seems to be several possible strategies for improving low-yielding cases while maintaining very short reaction times.
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202101/thumbnails/i_d0041_s2_10-1055_s-0040-1706021.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
Interestingly, with butane-2,3-dione and monohalogenated diamines, the products 3j and 3m were formed in very high 87% and 98% yields, respectively. Moreover, the 6-cyanosubstituted system 3n was formed in 90% yield. A synergetic electronic combination may occur in these particular systems ensuring rapid transformations. Further, diaryl diketones were briefly explored, and 3o was formed in near quantitative yield. The dimethyl and monochloro systems 3p,q were also formed in excellent 91% and 89% yields, respectively, whereas the monobromo system yielded only moderate amounts of 3r (51%). The chemistry is also compatible with substitution on the aryl diketone part, as the ortho-chlorosubstituted variant yielded 3s in 80% isolated yield. There seems to be some tolerance towards sterically crowded electrophiles. Next, heteroaryl diketones were employed with 2-furyl and 2-pyridyl substituents. These worked excellently to generate fairly complex multiheteroaromatic systems 3t–w in 75–96% yields. Finally, some unsymmetrical combinations were tested and 5-benzoylphenylenediamine in combination with 1,2-propanedione yielded excellent 96% of products 3x/3x′ as an equimolar isomeric mixture. An equimolar isomeric mixture was also observed with 1-phenyl-1,2-propanedione as electrophile, and 91% yield was isolated of 3y and 3y′. Lastly, 4,5-dimethylphenylenediamine was employed with indoyl-substituted oxocarboxylic acid 2z to generate the 2-hydroxy-3-(3-indoyl)-substituted quinoxaline 3z in moderate 41% yield (NMR). The yield was substantially improved upon microwave irradiation to 79%. In this case, one of the electrophilic sites is a carboxylic acid, and the diminished electrophilicity is likely the reason for the attenuated reactivity. In general, all products appeared to be stable upon isolation and storage, so this cannot explain any diminished chemical yields. The compounds 3f, 3y, and 3z are novel molecules.[42] Overall, the rapid quinoxaline formation appears to have rather broad scope with good to excellent yields obtainable in most cases and with temperature increase or simple acid catalysis as strategies to boost yields in problematic cases.
Based on the results herein, and a comparison with many of the literature studies employing various catalysts, heating, and prolonged reaction times, it is tempting to conclude that many studies lack an important control experiment without added catalyst. Moreover, prolonged reaction times and the need for heating of simple substrates may even suggest that the ‘catalysts’ employed in some cases actually decrease the reaction rates. This could occur if a metal predominantly coordinates with one or both of the substrates and thus, would reduce the effective concentration of reacting species and require more time or energy to effect an acceptable reaction outcome.
Based on these considerations and the results in this paper, we would like to strongly advocate that synthetic studies of quinoxaline formation using the classical condensation reaction should commence with the simple conditions described herein and that any novel catalytic reactions should be compared directly to the ‘uncatalyzed’ counterpart to assess the true catalyst performance. Lastly, it should be widely known and intuitive for practicing synthetic chemists that this classical condensation reaction can occur in minutes and without addition of catalysts. This does not appear to be the case upon examination of the literature.
In order to demonstrate further the applicability of these reaction conditions, five examples were conducted in experiments on larger scales (Scheme [3]).[41] Compounds 3α, 3o, and 3w were generated in high to excellent yields (91%, 70%, and 94% respectively) at 1 g scale using the basic conditions and methanol as solvent. If the reaction solvent was ethyl acetate, this would streamline the workup considerably since removal of the reaction solvent becomes unnecessary. Thus, we conducted the reaction at 10 g scale in ethyl acetate and quinoxalines 3a and 3α were readily isolated in impressive 93% and 85% yields, respectively. This study strongly suggests that this should be a method of choice for the construction of such structures on scale.
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202101/thumbnails/i_d0041_s3_10-1055_s-0040-1706021.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
In summary, we have revisited a classical transformation and report on improved synthesis efficiency and broadened scope of quinoxaline formation via the rapid condensation between aryldiamines and 1,2-dicarbonyl compounds. The cyclocondensation occurs fast under remarkably simple reaction conditions in medium to excellent chemical yields. Using methanol as solvent, the reaction typically proceeds at room temperature, open to air, and with only 1 minute reaction time. Problematic cases can be solved with simple acid catalysis or heating while maintaining very short reaction times. The practical nature and scalability of this green approach makes it an obvious starting point and method-of-choice for the synthesis of a range of quinoxalines.
#
Acknowledgment
The authors wish to acknowledge the Department of Chemistry at UiT The Arctic University of Norway for staff support during this project.
Supporting Information
- Supporting information for this article is available online at https://doi.org/10.1055/s-0040-1706021.
- Supporting Information
-
References and Notes
- 1a Gazit A, App H, McMahon G, Chen J, Levitzki A, Bohmer FD. J. Med. Chem. 1996; 39: 2170
- 1b Sehlstedt U, Aich P, Bergman J, Vallberg H, Norden B, Graslund A. J. Mol. Biol. 1998; 278: 31
- 2a Sakata G, Makino K, Kuraswa Y. Heterocycles 1988; 27: 2481
- 2b He W, Meyers MR, Hanney B, Spada A, Blider G, Galzeinski H, Amin D, Needle S, Page K, Jayyosi Z, Perrone H. Bioorg. Med. Chem. Lett. 2003; 13: 3097
- 2c Kim YB, Kim Y.-H, Park JY, Kim SK. Bioorg. Med. Chem. Lett. 2004; 14: 541
- 3a Gao H, Huang K.-C, Yamasaki EF, Chan KK, Chohan L, Snapka RM. Proc. Natl. Acad. Sci. U.S.A. 1999; 96: 12168
- 3b Cole SP, Bhardwaj G, Gerlach JH. Science 1992; 258: 1650
- 3c Lawrence DS, Copper JE, Smith CD. J. Med. Chem. 2001; 44: 594
- 3d Yoo HW, Suh ME, Park SW. J. Med. Chem. 1998; 41: 4716
- 3e Weng Q, Wang D, Guo P. Eur. J. Pharmacol. 2008; 581: 262
- 4a Tandon VK, Yadav DB, Maurya HK, Chaturvedi AK, Shukla PK. J. Med. Chem. 2006; 14: 6120
- 4b Carta A, Loriga M, Paglietti G. Eur. J. Med. Chem. 2004; 39: 195
- 5a Fonseca T, Gigante B, Marques MM, Gilchrist TL, De Clercq E. Bioorg. Med. Chem. 2004; 12: 103
- 5b Ali I, Al-Masoudi I, Hassan HG, Al-Masoudi N. Chem. Heterocycl. Compd. 2007; 43: 1052
- 6a Crowther AF, Curd FH.S, Davey DG, Stacey GJ. J. Chem. Soc. 1949; 1260
- 6b Rangisetty JB, Gupta CN. V. H. B, Prasad AL, Srinivas P, Sridhar N, Parimoo P, Veeranjaneyulu A. J. Pharm. Pharmacol. 2001; 53: 1409
- 7a Kotharkar SA, Shinde DB. Bioorg. Med. Chem. Lett. 2006; 16: 6181
- 7b Mashevskaya IV, Makhmudov RR, Aleksandrova GA, Golovnira OV, Duvalov AV, Maslivets AN. Pharm. Chem. J. 2001; 35: 196
- 7c Vyas DA, Chauhan NA, Parikh AR. Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 2007; 46: 1699
- 8 Gao H, Yamasaki EF, Chan KK, Shen LL, Snapka RM. Cancer Res. 2000; 60: 5937
- 9a Sonawane ND, Rangnekar DW. J. Heterocycl. Chem. 2002; 39: 303
- 9b Katoh A, Yoshida T, Ohkanda J. Heterocycles 2000; 52: 911
- 10a Dailey S, Feast WJ, Peace RJ, Sage IC, Till S, Wood EL. J. Mater. Chem. 2001; 11: 2238
- 10b Brien D, Weaver MS, Lidzey DG, Bradley DD. C. Appl. Phys. Lett. 1996; 69: 881
- 11 Sessler JL, Maeda H, Mizuno T, Lynch VM, Furuta H. Chem. Commun. 2002; 862
- 12 Ott S, Faust R. Synlett 2004; 1509
- 13a Sessler JL, Maeda H, Mizuno T, Lynch VM, Furuta H. J. Am. Chem. Soc. 2002; 124: 13474
- 13b Castro PP, Zhao G, Masangkay GA, Hernandez C, Gutierrez-Tunstad LM. Org. Lett. 2004; 6: 333
- 14 Thomas KR. J, Velusamy M, Lin JT, Chuen C.-H, Tao Y.-T. Chem. Mater. 2005; 17: 1860
- 15a Kazunobu T, Ryusuke T, Tomohiro O, Shuichi M. Chem. Commun. 2002; 212
- 15b Hegedus LS, Greenberg MM, Wendling JJ, Bullock JP. J. Org. Chem. 2003; 68: 4179
- 16a Raw SA, Wilfred CD, Taylor RJ. K. Org. Biomol. Chem. 2004; 2: 788
- 16b Dell A, William DH, Morris HR, Smith GA, Feeney J, Roberts GC. K. J. Am. Chem. Soc. 1975; 97: 2497
- 16c Bailly C, Echepare S, Gago F, Waring M. J. Anti-Cancer Drug Des. 1999; 15: 291
- 17a Abu-Hashem AA. Am. J. Org. Chem. 2015; 5: 14
- 17b Mamedov VA. In Quinoxalines 2016; 5
- 17c von Pechmann H. Ber. Dtsch. Chem. Ges. 1888; 21: 1411
- 17d Zincke T, Schmidt M. Justus Liebigs Ann. Chem. 1895; 286: 43
- 18a Brown DJ. In The Chemistry of Heterocyclic Compounds, Quinoxalines, Suppl. II. Taylor EC. Wiley; Hoboken: 2004
- 18b More SV, Sastry MN. V, Yao C.-F. Green Chem. 2006; 8: 91
- 18c Ajaikumar S, Pandurangan A. Appl. Catal., A 2009; 357: 184
- 18d Liu J.-Y, Liu J, Wang J.-D, Jiao D.-Q, Liu H.-W. Synth. Commun. 2010; 40: 2047
- 18e Kumbhar A, Kamble S, Barge M, Rashinkar G, Salunkhe R. Tetrahedron Lett. 2012; 53: 2756
- 18f Kadam HK, Khan S, Kunkalkar RA, Tilve SG. Tetrahedron Lett. 2013; 54: 1003
- 18g Arde SM, Patil AD, Mane AH, Salokhe PR, Salunkhe RS. Res. Chem. Intermed. 2020; 46: 5069
- 18h Rewcastle GW, Denny WA, Baguley BC. J. Med. Chem. 1987; 30: 843
- 19a Cho CS, Oh SG. Tetrahedron Lett. 2006; 47: 5633
- 19b Bera A, Sk M, Singh K, Banerjee D. Chem. Commun. 2019; 55: 5958
- 19c Daw P, Kumar A, Espinosa-Jalapa NA, Posner YD, David YB, Milstein D. ACS Catal. 2018; 8: 7734
- 19d Shee S, Ganguli K, Jana K, Kundu S. Chem. Commun. 2018; 54: 6883
- 19e Hille T, Irrgang T, Kempe R. Chem. Eur. J. 2014; 20: 5569
- 19f Mondal A, Sahoo MK, Subaramanian M, Balaraman E. J. Org. Chem. 2020; 85: 7181
- 20a Raw SA, Wilfred CD, Taylor RJ. K. Chem. Commun. 2003; 2286
- 20b Raw SA, Wilfred CD, Taylor RJ. K. Org. Biomol. Chem. 2004; 2: 788
- 20c Kim SY, Park KH, Chung YK. Chem. Commun. 2005; 1321
- 20d Cho CS, Oh SG. J. Mol. Catal. A.: Chem. 2007; 276: 205
- 21 Das B, Venkateswarlu K, Suneel K, Majhi A. Tetrahedron Lett. 2007; 48: 5371
- 22a Wan JP, Gan S.-F, Wu J.-M, Pan Y.-J. Green Chem. 2009; 11: 1633
- 22b Villemin D, Martin B. Synth. Commun. 1995; 25: 2319
- 22c Juncai F, Yang L, Qinghua M, Bin L. Synth. Commun. 1998; 28: 193
- 22d Vázquez E, De La Hoz A, Elander N, Moreno A, Stone-Elander S. Heterocycles 2001; 55: 109
- 22e Goswami S, Adak AK. Tetrahedron Lett. 2002; 43: 8371
- 22f Zhao Z, Wisnoski DD, Wolkenberg SE, Leister WH, Wang Y, Lindsley CW. Tetrahedron Lett. 2004; 45: 4873
- 22g Kim SY, Park KH, Chung YK. Chem. Commun. 2005; 1321
- 22h Kidwai M, Saxena S, Mohan R. J. Korean Chem. Soc. 2005; 49: 288
- 22i Azizian J, Karimi AR, Kazemizadeh Z, Mohammadi AA, Mohammadizadeh MR. Tetrahedron Lett. 2005; 46: 6155
- 22j Gris J, Glisoni R, Fabian L, Fernández B, Moglioni AG. Tetrahedron Lett. 2008; 49: 1053
- 23 Wu Z, Ede NJ. Tetrahedron Lett. 2001; 42: 8115
- 24 Sadjadi S, Sadjadi S, Hekmatshoar R. Ultrason. Sonochem. 2010; 17: 764
- 25a Jafarpour M, Rezaeifard A, Danehchin M. Appl. Catal. A 2011; 394: 48
- 25b Zhou JF, Gong GX, Shi KB, Zhi SJ. Chin. Chem. Lett. 2009; 20: 672
- 25c Krishnakumar B, Velmurugan R, Jothivel S, Swaminathan M. Catal. Commun. 2010; 11: 997
- 25d Niknam K, Saberi D, Mohagheghnejad M. Molecules 2009; 14: 1915
- 25e Darabi HR, Mohandessi S, Aghapoor K, Mohsenzadeh F. Catal. Commun. 2007; 8: 389
- 26 More SV, Sastry MN. V, Wang CC, Ching-Fa Y. Tetrahedron Lett. 2005; 46: 6345
- 27 Islami MR, Hassani Z. ARKIVOC 2008; (xv): 280
- 28 Bhosale RS, Sarda SR, Ardhapure SS, Jadhav WN, Bhusare SR, Pawar RP. Tetrahedron Lett. 2005; 46: 7183
- 29 Kumar A, Kumar S, Saxena A, De A, Mozumdar S. Catal. Commun. 2008; 9: 778
- 30 Dong F, Gong K, Fei Z, Zhou X, Liu Z. Catal. Commun. 2008; 9: 317
- 31 Darabi HR, Tahoori F, Aghapoor K, Taala F, Mohsenzadeh F. J. Braz. Chem. Soc. 2008; 19: 1646
- 32 Jafarpour M, Rezaeifard A, Danehchin M. Appl. Catal. A 2011; 394: 48
- 33 Raw SA, Wilfred CD, Taylor RJ. K. Org. Biomol. Chem. 2004; 2: 788
- 34 Venkatesh C, Singh B, Mahata PK, IIa H, Junjappa H. Org. Lett. 2005; 7: 2169
- 35 Brown DJ. Quinoxalines . In The Chemistry of Heterocyclic Compounds, Vol. 61 . Taylor EC, Wipf P. John Wiley & Sons; Hoboken: 2004: 1
- 36 More SV, Sastry MN. V, Yao CF. Green Chem. 2006; 8: 91
- 37 Cai JJ, Zou JP, Pan XQ, Zhang W. Tetrahedron Lett. 2008; 49: 7386
- 38 Heravi MM, Taheri S, Bakhtiari K, Oskooie HA. Catal. Commun. 2007; 8: 211
- 39 Darabi HR, Mohandessi S, Aghapoor K, Mohsenzadeh F. Catal. Commun. 2007; 8: 389
- 40 Elumalai V, Hansen JH. Synlett 2020; 31: 547
- 41 Typical ProcedureIn a 25 mL round-bottom flask was added benzene-1,2-diamine (1a, 100 mg, 0.925 mmol) which was dissolved in MeOH (5 mL). To the stirred solution, glyoxal (2a, 40%, 134 mg, 0.11 mL, 0.925 mmol) was added and the mixture stirred for 1 min at ambient temperature, followed by quenching with water (10 mL), dilution with ethyl acetate (50 mL), and washing with water (30 mL). The water layer was extracted with ethyl acetate (2 × 30 mL), the organic layers were combined, and dried over anhydrous Na2SO4. The drying agent was removed by filtration, and the solvent was evaporated under reduced pressure to obtain the desired product 3a as a yellowish liquid (0.111 g, 93%) without column purification (GC purity >99%). 1H NMR (400 MHz, CDCl3): δ = 8.84 (s, 2 H), 8.11 (dd, J = 6.4, 3.5 Hz, 2 H), 7.78 (dd, J = 6.4, 3.5 Hz, 2 H). 13C NMR (101 MHz, CDCl3): δ = 145.0, 143.1, 130.1, 129.5.From 1-gram-scale SynthesisCompound 3w was obtained as golden-yellow solid (1.710 g, 94%) without column purification (GC purity >99%). 1H NMR (400 MHz, CDCl3): δ = 8.51 (d, J = 1.9 Hz, 1 H), 8.33–8.21 (m, 4 H), 7.95 (dt, J = 7.8, 1.1 Hz, 1 H), 7.89–7.80 (m, 3 H), 7.75 (dtd, J = 13.2, 7.7, 1.8 Hz, 2 H), 7.60–7.51 (m, 1 H), 7.48–7.41 (m, 2 H), 7.18 (dddd, J = 7.7, 6.3, 5.1, 1.2 Hz, 2 H). 13C NMR (101 MHz, CDCl3): δ = 195.7, 157.1, 157.0, 154.1, 153.6, 148.7, 148.7, 142.9, 140.2, 138.8, 137.1, 136.8, 136.8, 132.9, 132.5, 130.4, 130.2, 129.9, 128.6, 124.4, 124.2, 123.4, 123.3.
- 42 Although there are only 3 novel compounds produced in this study, we have provided the NMR spectra for all entries in order to demonstrate the purity of the products after the indicated procedure. These can be found in the Supporting Information.
For some recent overviews, see:
For some historical references to the imine formation reaction, see:
For an example of a reaction in refluxing methanol without other additives, see:
Corresponding Author
Publication History
Received: 03 November 2020
Accepted after revision: 08 January 2021
Article published online:
10 February 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References and Notes
- 1a Gazit A, App H, McMahon G, Chen J, Levitzki A, Bohmer FD. J. Med. Chem. 1996; 39: 2170
- 1b Sehlstedt U, Aich P, Bergman J, Vallberg H, Norden B, Graslund A. J. Mol. Biol. 1998; 278: 31
- 2a Sakata G, Makino K, Kuraswa Y. Heterocycles 1988; 27: 2481
- 2b He W, Meyers MR, Hanney B, Spada A, Blider G, Galzeinski H, Amin D, Needle S, Page K, Jayyosi Z, Perrone H. Bioorg. Med. Chem. Lett. 2003; 13: 3097
- 2c Kim YB, Kim Y.-H, Park JY, Kim SK. Bioorg. Med. Chem. Lett. 2004; 14: 541
- 3a Gao H, Huang K.-C, Yamasaki EF, Chan KK, Chohan L, Snapka RM. Proc. Natl. Acad. Sci. U.S.A. 1999; 96: 12168
- 3b Cole SP, Bhardwaj G, Gerlach JH. Science 1992; 258: 1650
- 3c Lawrence DS, Copper JE, Smith CD. J. Med. Chem. 2001; 44: 594
- 3d Yoo HW, Suh ME, Park SW. J. Med. Chem. 1998; 41: 4716
- 3e Weng Q, Wang D, Guo P. Eur. J. Pharmacol. 2008; 581: 262
- 4a Tandon VK, Yadav DB, Maurya HK, Chaturvedi AK, Shukla PK. J. Med. Chem. 2006; 14: 6120
- 4b Carta A, Loriga M, Paglietti G. Eur. J. Med. Chem. 2004; 39: 195
- 5a Fonseca T, Gigante B, Marques MM, Gilchrist TL, De Clercq E. Bioorg. Med. Chem. 2004; 12: 103
- 5b Ali I, Al-Masoudi I, Hassan HG, Al-Masoudi N. Chem. Heterocycl. Compd. 2007; 43: 1052
- 6a Crowther AF, Curd FH.S, Davey DG, Stacey GJ. J. Chem. Soc. 1949; 1260
- 6b Rangisetty JB, Gupta CN. V. H. B, Prasad AL, Srinivas P, Sridhar N, Parimoo P, Veeranjaneyulu A. J. Pharm. Pharmacol. 2001; 53: 1409
- 7a Kotharkar SA, Shinde DB. Bioorg. Med. Chem. Lett. 2006; 16: 6181
- 7b Mashevskaya IV, Makhmudov RR, Aleksandrova GA, Golovnira OV, Duvalov AV, Maslivets AN. Pharm. Chem. J. 2001; 35: 196
- 7c Vyas DA, Chauhan NA, Parikh AR. Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 2007; 46: 1699
- 8 Gao H, Yamasaki EF, Chan KK, Shen LL, Snapka RM. Cancer Res. 2000; 60: 5937
- 9a Sonawane ND, Rangnekar DW. J. Heterocycl. Chem. 2002; 39: 303
- 9b Katoh A, Yoshida T, Ohkanda J. Heterocycles 2000; 52: 911
- 10a Dailey S, Feast WJ, Peace RJ, Sage IC, Till S, Wood EL. J. Mater. Chem. 2001; 11: 2238
- 10b Brien D, Weaver MS, Lidzey DG, Bradley DD. C. Appl. Phys. Lett. 1996; 69: 881
- 11 Sessler JL, Maeda H, Mizuno T, Lynch VM, Furuta H. Chem. Commun. 2002; 862
- 12 Ott S, Faust R. Synlett 2004; 1509
- 13a Sessler JL, Maeda H, Mizuno T, Lynch VM, Furuta H. J. Am. Chem. Soc. 2002; 124: 13474
- 13b Castro PP, Zhao G, Masangkay GA, Hernandez C, Gutierrez-Tunstad LM. Org. Lett. 2004; 6: 333
- 14 Thomas KR. J, Velusamy M, Lin JT, Chuen C.-H, Tao Y.-T. Chem. Mater. 2005; 17: 1860
- 15a Kazunobu T, Ryusuke T, Tomohiro O, Shuichi M. Chem. Commun. 2002; 212
- 15b Hegedus LS, Greenberg MM, Wendling JJ, Bullock JP. J. Org. Chem. 2003; 68: 4179
- 16a Raw SA, Wilfred CD, Taylor RJ. K. Org. Biomol. Chem. 2004; 2: 788
- 16b Dell A, William DH, Morris HR, Smith GA, Feeney J, Roberts GC. K. J. Am. Chem. Soc. 1975; 97: 2497
- 16c Bailly C, Echepare S, Gago F, Waring M. J. Anti-Cancer Drug Des. 1999; 15: 291
- 17a Abu-Hashem AA. Am. J. Org. Chem. 2015; 5: 14
- 17b Mamedov VA. In Quinoxalines 2016; 5
- 17c von Pechmann H. Ber. Dtsch. Chem. Ges. 1888; 21: 1411
- 17d Zincke T, Schmidt M. Justus Liebigs Ann. Chem. 1895; 286: 43
- 18a Brown DJ. In The Chemistry of Heterocyclic Compounds, Quinoxalines, Suppl. II. Taylor EC. Wiley; Hoboken: 2004
- 18b More SV, Sastry MN. V, Yao C.-F. Green Chem. 2006; 8: 91
- 18c Ajaikumar S, Pandurangan A. Appl. Catal., A 2009; 357: 184
- 18d Liu J.-Y, Liu J, Wang J.-D, Jiao D.-Q, Liu H.-W. Synth. Commun. 2010; 40: 2047
- 18e Kumbhar A, Kamble S, Barge M, Rashinkar G, Salunkhe R. Tetrahedron Lett. 2012; 53: 2756
- 18f Kadam HK, Khan S, Kunkalkar RA, Tilve SG. Tetrahedron Lett. 2013; 54: 1003
- 18g Arde SM, Patil AD, Mane AH, Salokhe PR, Salunkhe RS. Res. Chem. Intermed. 2020; 46: 5069
- 18h Rewcastle GW, Denny WA, Baguley BC. J. Med. Chem. 1987; 30: 843
- 19a Cho CS, Oh SG. Tetrahedron Lett. 2006; 47: 5633
- 19b Bera A, Sk M, Singh K, Banerjee D. Chem. Commun. 2019; 55: 5958
- 19c Daw P, Kumar A, Espinosa-Jalapa NA, Posner YD, David YB, Milstein D. ACS Catal. 2018; 8: 7734
- 19d Shee S, Ganguli K, Jana K, Kundu S. Chem. Commun. 2018; 54: 6883
- 19e Hille T, Irrgang T, Kempe R. Chem. Eur. J. 2014; 20: 5569
- 19f Mondal A, Sahoo MK, Subaramanian M, Balaraman E. J. Org. Chem. 2020; 85: 7181
- 20a Raw SA, Wilfred CD, Taylor RJ. K. Chem. Commun. 2003; 2286
- 20b Raw SA, Wilfred CD, Taylor RJ. K. Org. Biomol. Chem. 2004; 2: 788
- 20c Kim SY, Park KH, Chung YK. Chem. Commun. 2005; 1321
- 20d Cho CS, Oh SG. J. Mol. Catal. A.: Chem. 2007; 276: 205
- 21 Das B, Venkateswarlu K, Suneel K, Majhi A. Tetrahedron Lett. 2007; 48: 5371
- 22a Wan JP, Gan S.-F, Wu J.-M, Pan Y.-J. Green Chem. 2009; 11: 1633
- 22b Villemin D, Martin B. Synth. Commun. 1995; 25: 2319
- 22c Juncai F, Yang L, Qinghua M, Bin L. Synth. Commun. 1998; 28: 193
- 22d Vázquez E, De La Hoz A, Elander N, Moreno A, Stone-Elander S. Heterocycles 2001; 55: 109
- 22e Goswami S, Adak AK. Tetrahedron Lett. 2002; 43: 8371
- 22f Zhao Z, Wisnoski DD, Wolkenberg SE, Leister WH, Wang Y, Lindsley CW. Tetrahedron Lett. 2004; 45: 4873
- 22g Kim SY, Park KH, Chung YK. Chem. Commun. 2005; 1321
- 22h Kidwai M, Saxena S, Mohan R. J. Korean Chem. Soc. 2005; 49: 288
- 22i Azizian J, Karimi AR, Kazemizadeh Z, Mohammadi AA, Mohammadizadeh MR. Tetrahedron Lett. 2005; 46: 6155
- 22j Gris J, Glisoni R, Fabian L, Fernández B, Moglioni AG. Tetrahedron Lett. 2008; 49: 1053
- 23 Wu Z, Ede NJ. Tetrahedron Lett. 2001; 42: 8115
- 24 Sadjadi S, Sadjadi S, Hekmatshoar R. Ultrason. Sonochem. 2010; 17: 764
- 25a Jafarpour M, Rezaeifard A, Danehchin M. Appl. Catal. A 2011; 394: 48
- 25b Zhou JF, Gong GX, Shi KB, Zhi SJ. Chin. Chem. Lett. 2009; 20: 672
- 25c Krishnakumar B, Velmurugan R, Jothivel S, Swaminathan M. Catal. Commun. 2010; 11: 997
- 25d Niknam K, Saberi D, Mohagheghnejad M. Molecules 2009; 14: 1915
- 25e Darabi HR, Mohandessi S, Aghapoor K, Mohsenzadeh F. Catal. Commun. 2007; 8: 389
- 26 More SV, Sastry MN. V, Wang CC, Ching-Fa Y. Tetrahedron Lett. 2005; 46: 6345
- 27 Islami MR, Hassani Z. ARKIVOC 2008; (xv): 280
- 28 Bhosale RS, Sarda SR, Ardhapure SS, Jadhav WN, Bhusare SR, Pawar RP. Tetrahedron Lett. 2005; 46: 7183
- 29 Kumar A, Kumar S, Saxena A, De A, Mozumdar S. Catal. Commun. 2008; 9: 778
- 30 Dong F, Gong K, Fei Z, Zhou X, Liu Z. Catal. Commun. 2008; 9: 317
- 31 Darabi HR, Tahoori F, Aghapoor K, Taala F, Mohsenzadeh F. J. Braz. Chem. Soc. 2008; 19: 1646
- 32 Jafarpour M, Rezaeifard A, Danehchin M. Appl. Catal. A 2011; 394: 48
- 33 Raw SA, Wilfred CD, Taylor RJ. K. Org. Biomol. Chem. 2004; 2: 788
- 34 Venkatesh C, Singh B, Mahata PK, IIa H, Junjappa H. Org. Lett. 2005; 7: 2169
- 35 Brown DJ. Quinoxalines . In The Chemistry of Heterocyclic Compounds, Vol. 61 . Taylor EC, Wipf P. John Wiley & Sons; Hoboken: 2004: 1
- 36 More SV, Sastry MN. V, Yao CF. Green Chem. 2006; 8: 91
- 37 Cai JJ, Zou JP, Pan XQ, Zhang W. Tetrahedron Lett. 2008; 49: 7386
- 38 Heravi MM, Taheri S, Bakhtiari K, Oskooie HA. Catal. Commun. 2007; 8: 211
- 39 Darabi HR, Mohandessi S, Aghapoor K, Mohsenzadeh F. Catal. Commun. 2007; 8: 389
- 40 Elumalai V, Hansen JH. Synlett 2020; 31: 547
- 41 Typical ProcedureIn a 25 mL round-bottom flask was added benzene-1,2-diamine (1a, 100 mg, 0.925 mmol) which was dissolved in MeOH (5 mL). To the stirred solution, glyoxal (2a, 40%, 134 mg, 0.11 mL, 0.925 mmol) was added and the mixture stirred for 1 min at ambient temperature, followed by quenching with water (10 mL), dilution with ethyl acetate (50 mL), and washing with water (30 mL). The water layer was extracted with ethyl acetate (2 × 30 mL), the organic layers were combined, and dried over anhydrous Na2SO4. The drying agent was removed by filtration, and the solvent was evaporated under reduced pressure to obtain the desired product 3a as a yellowish liquid (0.111 g, 93%) without column purification (GC purity >99%). 1H NMR (400 MHz, CDCl3): δ = 8.84 (s, 2 H), 8.11 (dd, J = 6.4, 3.5 Hz, 2 H), 7.78 (dd, J = 6.4, 3.5 Hz, 2 H). 13C NMR (101 MHz, CDCl3): δ = 145.0, 143.1, 130.1, 129.5.From 1-gram-scale SynthesisCompound 3w was obtained as golden-yellow solid (1.710 g, 94%) without column purification (GC purity >99%). 1H NMR (400 MHz, CDCl3): δ = 8.51 (d, J = 1.9 Hz, 1 H), 8.33–8.21 (m, 4 H), 7.95 (dt, J = 7.8, 1.1 Hz, 1 H), 7.89–7.80 (m, 3 H), 7.75 (dtd, J = 13.2, 7.7, 1.8 Hz, 2 H), 7.60–7.51 (m, 1 H), 7.48–7.41 (m, 2 H), 7.18 (dddd, J = 7.7, 6.3, 5.1, 1.2 Hz, 2 H). 13C NMR (101 MHz, CDCl3): δ = 195.7, 157.1, 157.0, 154.1, 153.6, 148.7, 148.7, 142.9, 140.2, 138.8, 137.1, 136.8, 136.8, 132.9, 132.5, 130.4, 130.2, 129.9, 128.6, 124.4, 124.2, 123.4, 123.3.
- 42 Although there are only 3 novel compounds produced in this study, we have provided the NMR spectra for all entries in order to demonstrate the purity of the products after the indicated procedure. These can be found in the Supporting Information.
For some recent overviews, see:
For some historical references to the imine formation reaction, see:
For an example of a reaction in refluxing methanol without other additives, see:
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202101/thumbnails/i_d0041_f1_10-1055_s-0040-1706021.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202101/thumbnails/i_d0041_s1_10-1055_s-0040-1706021.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202101/i_d0041_t1_10-1055_s-0040-1706021.gif)
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202101/thumbnails/i_d0041_s2_10-1055_s-0040-1706021.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
![](https://www.thieme-connect.de/media/10.1055-s-00032269/202101/thumbnails/i_d0041_s3_10-1055_s-0040-1706021.gif)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)